Kornimate/medical-research-clean huggingface dataset:
study of albumin-bound paclitaxel (abraxane) in combination with carboplatin and herceptin in patients with advanced breast cancer

Conditions: Breast Cancer

Summary: this trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: albumin-bound paclitaxel (abi-007), carboplatin and herceptin. participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.


Eligibility criteria:
inclusion criteria: * confirmed adenocarcinoma of the breast * tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (her-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (fish)+ * stage iv disease * measurable disease * at least 3 weeks since prior cytotoxic chemotherapy * at least 4 weeks since radiotherapy with full recovery * at least 4 weeks since major surgery with full recovery * eastern cooperative oncology group (ecog) performance status 0-2 * at least 18 years old * absolute neutrophil count (anc) at least 1.5 x 10\^9 cells/l * platelets at least 100 x 10\^9 cells/l * hemoglobin at least 9 g/dl * aspartame aminotransferase (ast), alanine aminotransferase (alt) less than 2.5x upper limit normal * alkaline phosphatase less than 1.5x upper limit normal * creatinine less than 1.5 gm/dl * normal left ventricular ejection fraction * negative pregnancy test * agree to use method to avoid pregnancy * informed consent is obtained exclusion criteria: * up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. one year since taxane and herceptin treatment. * cumulative life-time dose of doxorubicin is greater than 360 mg/m\^2 * concurrent immunotherapy or hormonal therapy * parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment * serious intercurrent medical or psychiatric illness, including serious active infection * history of congestive heart failure * history of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer * patients who have received an investigational drug within the previous 3 weeks * patient is currently enrolled in another clinical study receiving investigational therapies * pregnant or nursing women

Keywords: advanced breast cancer
androgens level in the third trimester of pregnancy in patients with preeclampsia

Conditions: Pre-Eclampsia

Summary: this study aims to compare between androgens level (serum total and free testosterone) in women with preeclampsia and normal ones in the third trimester of pregnancy (28-40 weeks).

methodology: all women in this study will be subjected to: * all women are candidates for this study according to inclusion and exclusion criteria. * history taking with special emphases on last menstrual period to determine the exact gestational age. * a reliable date is defined as the occurrence of regular menstrual cycles (28±7 days) in patients who have not taken oral contraceptives during the three months before conception and have no irregular bleeding. * general and abdominal examination for each patient to determine those patients matching with the inclusion criteria. * preeclampsia refers to the new onset of hypertension (systolic blood pressure ≥140 mmhg ,or diastolic blood pressure≥ 90 mmhg ,or both, measured on two occasions \> 6 hours apart) and either proteinuria or end organ dysfunction after 20 weeks of gestation in a previously normotensive woman. * at ain shams university hospitals, the investigator will use elisa based test system intended for the quantitative measurement of total and free testosterone for patients of both groups.

Eligibility criteria:
inclusion criteria: 1. pregnant women (primigravidas) at third trimester i.e. 28-40 weeks. 2. age between 20 and 35 years old. 3. live fetus. 4. having no history of pregestational hypertension. 5. having no history of diseases associated with hormone disorders (thyroid gland disorders, dm, hyperprolactinemia or polycystic ovary syndrome). 6. during their pregnancy they did not receive antihypertensive medications. 7. nonsmoker. exclusion criteria: * 1- first and second trimester pregnant women. 2- women younger than 20 years old and older than 35 years old 3- intrauterine fetal death. 4- history of pregestational hypertension. 5- history of hormonal disorders (thyroid gland disorders and hyperprolactinemia). 6- smoker. 7- polycystic ovary syndrome. 8- signs or symptoms of hyper-androgenism (hirsutism, acne, oily skin, etc.). 9- diabetes mellitus. 10- drug use except ordinary supplementation (iron, folic acid).
coronary sinus reducer implantation for ischemia reduction

Conditions: Refractory Angina Pectoris

Summary: patients with refractory angina pectoris have low quality of life and reduced exertional capacity. studies have shown that the coronary sinus reducer (csr) implantation improves the quality of life. however, to date there are no firm objective data on improvement of exertional capacity. studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients. as angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %. the investigators will study weather the csr implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone. further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrecg markers of left ventricular arrhythmogenicity. 40 patients with refractory angina ccs class (canadian cardiovascular society) ii-iv and confirmed reversible ischemia will be included. patients will be randomized into two groups. the first group will undergo csr implantation procedure. the second group will present a sham control group with placebo procedure. at inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (cpet), single photon emission tomography for detection of reversible ischemia (spect), high resolution ecg (hrecg), echocardiography and asses the subjective burden of angina according to ccs score and the quality of life according to the seattle angina questionnaire (saq).


Eligibility criteria:
inclusion criteria: * angina pectoris ccs class ii-iv * receiving optimal medical therapy for at least one month * confirmed reversible myocardial ischemia in left anterior descending coronary artery (lad) and/or left circumflex coronary artery (lcx) territory by spect * not candidate for percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) exclusion criteria: * recent non stable angina pectoris (within 1 months) * recent acute coronary syndrome (within 3 months) * recent successful pci and/or cabg (within 6 months) * decompensated heart failure and/or recent (within 3 months) hospitalization due to heart failure * severe heart valve(s) disease * advanced chronic obstructive pulmonary disease (copd) or poorly managed asthma * peripheral arterial disease, musculoskeletal disorder or central nervous system disease which preclude exercise testing

Keywords: angina pectoris coronary sinus reducer quality of life reversible ischemia exercise testing oxygen consumption
medical gas humidification during noninvasive mechanical ventilation

Conditions: Respiration, Artificial; Critical Illness

Summary: in this study, the investigators aimed to study the role of medical gas humidification during noninvasive mechanical ventilation.

the medical gases are usually dry and cold thus when they are used during invasive mechanical ventilation they must be conditioned. no data are present on the necessity to condition the medical gases during non invasive mechanical ventilation. in this study the investigators studied the humidity and the temperature of the medical gases with and without any conditioning during non invasive mechanical ventilation in a group of healthy subjects and critically ill patients.

Eligibility criteria:
inclusion criteria: * critically ill patients requiring non invasive mechanical ventilation exclusion criteria: * comatose patients

Keywords: temperature humidity non invasive mechanical ventilation
observational prospective study describing the global patient care and follow-up of prostate cancer patients treated with degarelix

Conditions: Prostate Cancer

Summary: the duo study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by degarelix was introduced. this study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.


Eligibility criteria:
inclusion criteria: * male aged 18 years or older * diagnosed with prostate cancer * patient having received an antagonist of gnrh degarelix prescription. * agreeing to and capable of completing in french during the visits all questionnaires on the impact of their illness and treatment. * patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written informed consent form. exclusion criteria: * patient included in an interventional study assessing treatment for prostate cancer. * patient presenting hypersensitivity to degarelix or one of its excipients. * patient treated by other hormonotherapy.
telephone interview study for men and women with osteoarthritis

Conditions: Osteoarthritis

Summary: the telephone interviews will be conducted to gather information on goal setting and goal attainment from men and women with osteoarthritis.

interview data used to develop a new self-administered questionnaire

Eligibility criteria:
inclusion criteria: * between 40 and 80 years of age * have moderate to severe pain * diagnosed with osteoarthritis of the hip and/or knee at least 6 months ago * currently receiving treatment for osteoarthritis * able to speak and read english * us resident * willing to share your thoughts and experiences in a 45-minute telephone interview exclusion criteria:

Keywords: osteoarthritis, arthritis
prognostic influence of light rheography measurement of patients with secondary raynaud syndrome with ulcers on hands

Conditions: Raynaud's Phenomenon; Skin Necrosis

Summary: the purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary raynaud syndrome.

digital ulcers (du) belong to one of the most prevalent complications of systemic scleroses, leading in course to considerable impairment in everyday and professional life. the aetiology of the emergence of du in patients with systemic scleroses (ssc) is complex, whereas the disease itself is primarily characterized by a vasculopathy of the small arterial vessels. in the course of the disease this chronic infection leads to fibrotic intimal hyperplasia, adventitial fibrosis, and thus to a significant lumen narrowing. so far, a number of independent risk factors have been identified, such as male gender, chronic infections of the esophagus, pulmonary-arterial hypertension, evidence of specific antibodies (e.g. anti-scl70) in the blood, or the a previous manifestation of a raynoud syndrom.

Eligibility criteria:
inclusion criteria: * subjects with limited or diffuse systemic sclerosis/scleroderma with at least one ulcera at fingertip * age \> 18 years * weight \> 40 kg exclusion criteria: * sympathectomy * ulcers due to other condition (pvd, dm, thromboangiitis obliterans etc.) * antibiotic concomitant medication * therapy with prostanoids within the last 4 weeks * previous bosentan therapy * severe liver and renal insufficiency(creatinin \>2.0 mg/dl;ast/alt \> 3x unl) * severe cardiac- pulmonal diseases * untreated or therapy refractory hypertension * noncompliance * pregnancy or nursing (pregnancy test required)

Keywords: morbus raynaud ulcera hands, toes vasospastic disorder raynaud's phenomenon
correction of psoriatic t cell signatures by deucravacitinib

Conditions: Psoriasis Vulgaris

Summary: this study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the tyrosine kinase 2 (tyk2) blocker, deucravacitinib.

this is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. patients with moderate-severe psoriasis (bsa \>= 10%, pasi \>=12, static physician's global assessment (spga) 3 and above) exclusion criteria: 1. taking systemic immunosuppressives in the last 12 weeks 2. pregnancy 3. severe immunodeficiency (either from genetic or infectious causes). 4. tuberculosis or other active serious infection 5. active systemic malignancy. 6. breast-feeding 7. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
accuracy of dental movements using clear aligners treatment: a single-center prospective observational study

Conditions: Malocclusion

Summary: the aim of the present prospective observational study is to evaluate the accuracy of dental movements in the three planes of space, assessing the correspondence between the virtual planned movements and the clinical outcomes achieved using thermoformed or 3d printed orthodontic aligners. the study will include patients who are candidates for aligner orthodontics treatment. after having acquired the standard initial diagnostic data (clinical examination, intra- and extra-oral photographs, intra- and extra-oral scans, orthopantomography and lateral-lateral teleradiography of the skull), the digital impressions of the arches will be used to plan the dental movements necessary for correction of malocclusion. the aligners will then be designed using orthodontic cad software and realized using a thermoformed and direct 3d printing process. all patients will be treated following current recommendations relating to the orthodontic treatments in question. after delivery of the aligners, during each check-up, intra-oral and extra-oral scans will be acquired to evaluate the actual position of the teeth and, using special software will be compare the virtually designed position with tooth with the clinical outcomes. any discrepancies will be recorded and statistically analyzed.there are no additional invasive procedures. intra- and extra-oral scans will be acquired regularly to monitor the extent of tooth movement over time.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 65 years 2. good general health 3. presence of a dental/skeletal malocclusion 4. permanent dentition with second molars completely erupted in the arch 5. correct tooth shape, with sufficient height of the clinical crowns 6. good compliance during treatment exclusion criteria: 1. systemic diseases or pharmacological therapy with drugs that can affect orthodontic movement 2. orofacial malformations or syndromes 3. periodontal disease 4. smoke 5. pregnancy 6. signs and/or symptoms of temporomandibular disorders 7. absence of teeth (except for third molars) 8. dental implants

Keywords: clear aligner malocclusion direct print aligner
dynamic monitoring of ctdna predicts recurrence of advanced ovarian cancer after primary treatments

Conditions: Ovarian Cancer Stage IV; Ovarian Cancer Stage III

Summary: patients who receive satisfactory pds, currently the change in ca125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. this study plans to use ctdna dynamic monitoring to detect minimal residual lesions during treatment, to demonstrate the application value of ctdna dynamic monitoring in predicting the recurrence of ovarian cancer after pds/ids surgery.

this study plans to include ovarian cancer patients who have undergone pds/ids surgery. by analyzing the surgical tissue samples of ovarian cancer patients, we aim to identify risk factors related to the prognosis and recurrence of ovarian cancer. by monitoring the ctdna status after pds surgery, we analyze the role of ctdna-mrd in predicting postoperative recurrence of ovarian cancer. by monitoring the mrd status at the end of the 3rd cycle of adjuvant chemotherapy and at the end of adjuvant treatment, we analyze the predictive role of serial cdna-mrd for the efficacy of adjuvant treatment, providing a basis for determining the number of cycles of adjuvant treatment after pds.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old. 2. patients diagnosed with stage iiic-iva ovarian cancer through pathological examination. 3. the participant has read and fully understands the patient information, and has signed the informed consent form. 4. the patient is willing to undergo primary debulking surgery (pds) or interval debulking surgery（ids）. - exclusion criteria: 1. other tumors have been detected within the last 5 years. 2. organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants. 3. patients was deemed unsuitable to participate in this study by other researchers. 4. patients who have previously received neoadjuvant chemotherapy or targeted therapy.

Keywords: ctdna ovarian cancer pds ids adjuvant chemotherapy
the safety and effectiveness of megace in hiv-infected women

Conditions: Anorexia; Cachexia; HIV Infections

Summary: to further evaluate the safety of megestrol acetate (megace) oral suspension in the treatment of anorexia and cachexia in hiv-positive women. to compare the effectiveness of 2 doses of megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.

patients are randomized to receive 1 of 2 doses of megace oral suspension daily for 24 weeks; at 12 weeks, those receiving the lower dose who have not gained 5 pounds over baseline or had appetite improvement to good or excellent are escalated to the higher dose. patients are evaluated at 4-week intervals. dose may be adjusted to maintain a desired weight.

Eligibility criteria:
inclusion criteria patient must have: * hiv infection. * evidence of hiv wasting syndrome that includes anorexia (appetite fair or poor) and weight loss \>= 10 percent of pre-illness body weight. * perception of weight loss as a detriment. * life expectancy of at least 24 weeks. prior medication: allowed: * megestrol acetate for weight gain at a dose \< 400 mg for \< 60 days, provided therapy was discontinued at least 3 months prior to study entry. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * poorly controlled hypertension. * heart failure. * deep vein thrombosis. * uncontrolled severe diarrhea. * treatable active current infection (excluding chronic low-grade opportunistic infections). * unable to intake food. * impaired digestive/absorptive function. concurrent medication: excluded: * initiation during the study of any therapy to treat hiv or anorexia/cachexia (other than study drug). patients with the following prior conditions are excluded: * hospitalization for or exacerbation of illness associated with weight loss within the past 2 weeks. * participation in other investigational drug studies within the past month. * previous abnormal mammogram (if 35-40 years of age) or abnormal mammogram within the past year (if over 40 years of age). prior medication: excluded: * new antiviral therapy within the past 8 weeks. * medications to promote weight gain (e.g., corticosteroid, dronabinol) within the past 2 months. * megestrol acetate within the past 3 months. iv drug abuse not treated for at least 4 months.

Keywords: megestrol acquired immunodeficiency syndrome anorexia cachexia suspensions
study of metformin plus oligomeric procyanidin complex for pharmacologic manipulation of age (advanced glycation endproducts) levels in prostate cancer patients

Conditions: Prostate Cancer

Summary: the overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (opc) for pharmacologic reduction of age levels in patients with prostate cancer.

ages (advanced glycation endpoints) are a type of metabolite, or substance, found in the food. the age content in food is determined by the types of food you eat and also how you prepare your food. the researchers helping conduct this study have found a potential link between age levels and cancer. the purpose of this study is to identify safe pharmaceutical agents that can reduce the age levels in subjects with advanced cancer.

Eligibility criteria:
inclusion criteria: 1. confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer. 2. subjects must be receiving adt with a gnrh agonist or antagonist, with or without an anti-androgen, with a current testosterone level documented to be \<50ng/dl at enrollment. subjects whose adt is interrupted may enroll or continue on study as long as the testosterone is documented to remain \<50ng/dl for the entire duration of study participation. subjects who have undergone orchiectomy are also eligible. 3. subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows: * hematology parameters: anc \>1000/mcl, platelets \> 100,000/mcl, hgb \>8.0gm/dl * renal function: egfr of ≥ 45mls/min using cockkroft and gault formula (see appendix c). * liver function: total bilirubin ≤uln, ast and alt \<1.5xuln, prior radiation therapy allowed 4. subjects may have diabetes mellitus but must not be taking metformin. 5. able to swallow and retain oral medication 6. ecog performance status of 0 - 2 7. ability to sign written informed consent 8. testosterone level \<50ng/dl at time of enrollment. 9. age 18 or older. exclusion criteria: 1. known allergy to grapes or grape seed 2. known hypersensitivity or intolerance to metformin. 3. any condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as nyha class iii or iv functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day). 4. prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with genomically-targeted agents, or provenge is allowed. 5. history of receiving more than 2 classes of adt. 6. current use of metformin, or strong antioxidants (extracts from grape seed, milk thistle; pine bark, green tea, saw palmetto; resveratrol; flavonoids; catechins; ellagic acid), large quantities of red grapes, white button mushrooms, red wine 7. psa doubling time of \<6 months, measured over the 3 months prior to enrollment.
18f-fluorocholine (18f-fcho) to distinguish necrosis from recurrence in brain metastases

Conditions: Brain Metastases

Summary: the main purpose of this study is to determine the distribution of 18f fluorocholine (18f-fch) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. in addition, the study will measure levels of 18f-fch in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.


Eligibility criteria:
inclusion criteria: * patient and/or guardian is able to provide written informed consent prior to study registration * age ≥ 21 years old * evolving brain lesions post srs requiring neurosurgical resection (whether for symptomatic control or to establish pathology) exclusion criteria: * inability to undergo a mri or pet scan (e.g., claustrophobia or metal implant) * pregnant or nursing female * unable to cooperate for pet/ct

Keywords: 18f-fluorocholine (18f-fcho) pet scan mri 13-199